Literature DB >> 11124037

Identification of the phospholipid-binding site of human beta(2)-glycoprotein I domain V by heteronuclear magnetic resonance.

M Hoshino1, Y Hagihara, I Nishii, T Yamazaki, H Kato, Y Goto.   

Abstract

To understand the mechanism of the interaction between human beta(2)-glycoprotein I (beta(2)-GPI) and negatively charged phospholipids, we determined the three-dimensional solution structure of the fifth domain of beta(2)-GPI by heteronuclear multidimensional NMR. The results showed that the molecule is composed of well-defined four anti-parallel beta-strands and two short alpha-helices, as well as a long highly flexible loop. Backbone dynamic analysis demonstrated significant mobility of the flexible loop on a subnanosecond time scale. Structural modeling of the nicked fifth domain, in which the Lys317-Thr318 peptide bond was specifically cleaved, revealed the importance of this long C-terminal loop for the interaction between beta(2)-GPI and negatively charged phospholipids. A titration experiment with the anionic surfactant SDS showed that this highly mobile loop, as well as the short beta-hairpin between betaC and betaD strands, which is rich in positively charged residues, specifically interact with the surfactant. The mobile loop, together with the surrounding positively charged residues, probably construct the binding site for negatively charged phospholipids such as cardiolipin. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11124037     DOI: 10.1006/jmbi.2000.4243

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  9 in total

1.  The interaction of beta(2)-glycoprotein I domain V with chaperonin GroEL: the similarity with the domain V and membrane interaction.

Authors:  Masayo Gozu; Masaru Hoshino; Takashi Higurashi; Hisao Kato; Yuji Goto
Journal:  Protein Sci       Date:  2002-12       Impact factor: 6.725

2.  Chemical synthesis and characterization of wild-type and biotinylated N-terminal domain 1-64 of beta2-glycoprotein I.

Authors:  Nicola Pozzi; Alessandra Banzato; Samuele Bettin; Elisa Bison; Vittorio Pengo; Vincenzo De Filippis
Journal:  Protein Sci       Date:  2010-05       Impact factor: 6.725

3.  Biotinylation of glycan chains in beta2 glycoprotein I induces dimerization of the molecule and its detection by the human autoimmune anti-cardiolipin antibody EY2C9.

Authors:  Arnaud Dupuy D'Angeac; Ilias Stefas; Hubert Graafland; Frédéric De Lamotte; Marcel Rucheton; Caroline Palais; Anna-Karin Eriksson; Priscille Bosc; Caroline Rosé; Robert Chicheportiche
Journal:  Biochem J       Date:  2006-01-01       Impact factor: 3.857

Review 4.  Atherosclerosis in autoimmune diseases.

Authors:  Eiji Matsuura; Kazuko Kobayashi; Luis R Lopez
Journal:  Curr Rheumatol Rep       Date:  2009-02       Impact factor: 4.592

5.  Beta 2-Glycoprotein I binds factor XI and inhibits its activation by thrombin and factor XIIa: loss of inhibition by clipped beta 2-glycoprotein I.

Authors:  Tong Shi; G Michael Iverson; Jian C Qi; Keith A Cockerill; Matthew D Linnik; Pamela Konecny; Steven A Krilis
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-08       Impact factor: 11.205

6.  Recombinant hepatitis B surface antigen and anionic phospholipids share a binding region in the fifth domain of beta2-glycoprotein I (apolipoprotein H).

Authors:  Haider Mehdi; Asma Naqvi; M Ilyas Kamboh
Journal:  Biochim Biophys Acta       Date:  2008-01-12

7.  Increase in the conformational flexibility of beta 2-microglobulin upon copper binding: a possible role for copper in dialysis-related amyloidosis.

Authors:  James Villanueva; Masaru Hoshino; Hidenori Katou; József Kardos; Kazuhiro Hasegawa; Hironobu Naiki; Yuji Goto
Journal:  Protein Sci       Date:  2004-02-06       Impact factor: 6.725

8.  Identification of the binding site for fondaparinux on Beta2-glycoprotein I.

Authors:  Alexey Kolyada; Alfredo De Biasio; Natalia Beglova
Journal:  Biochim Biophys Acta       Date:  2013-06-25

9.  Recombinant domain V of β2-glycoprotein I inhibits the formation of atherogenic oxLDL/β2-glycoprotein I complexes.

Authors:  Jingda Li; Yan Chi; Shuqian Liu; Le Wang; Renjun Wang; Xiaofei Han; Eiji Matsuura; Qingping Liu
Journal:  J Clin Immunol       Date:  2014-06-27       Impact factor: 8.317

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.